Media stories about Vericel (NASDAQ:VCEL) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vericel earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.9700137058879 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Vericel (NASDAQ:VCEL) traded down $0.05 during midday trading on Thursday, reaching $6.95. 287,800 shares of the company’s stock traded hands, compared to its average volume of 775,858. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.50 and a quick ratio of 2.22. The stock has a market capitalization of $244.35, a price-to-earnings ratio of -7.90 and a beta of 3.34. Vericel has a 52 week low of $2.35 and a 52 week high of $8.25.

Several brokerages recently weighed in on VCEL. ValuEngine upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $9.00 price target on shares of Vericel in a research report on Tuesday, January 2nd. Finally, BTIG Research set a $8.00 price objective on shares of Vericel and gave the stock a “buy” rating in a research note on Tuesday, January 2nd.

TRADEMARK VIOLATION WARNING: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with's FREE daily email newsletter.